Efficacy and Safety of Spesolimab in Patients With Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of the European Academy of Dermatology and Venereology: JEADV
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, double-blind, placebo-controlled, phase IIa study
J Eur Acad Dermatol Venereol 2022 Nov 14;[EPub Ahead of Print], R Bissonnette, W Abramovits, É Saint-Cyr Proulx, P Lee, E Guttman-Yassky, E Zovko, R Sigmund, J Willcox, T BieberFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.